Vasoactive agent intraocular implant

• US 20070260203A1
• Filed: 05/04/2006
• Published: 11/08/2007
• Est. Priority Date: 05/04/2006
• Status: Abandoned Application

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Yang, Rong, Donello, John
• Application Number:
  US11/417,420
• Publication Number:
  US 20070260203A1
• Time in Patent Office: Days
• US Class Current: 604/294
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Intraocular implants comprising a vasoactive compound and a polymer useful for treating an ocular condition. The vasoactive compound can be a vasodilator. The polymer can be a biodegradable polymer, and the ocular condition can be glaucoma.

Claims

1. An intraocular implant for treating an ocular condition, the implant comprising:

(a) a vasoactive compound, and;

(b) a carrier associated with the vasoactive compound, thereby forming an intraocular implant suitable for treating an ocular condition.

2. The method of claim 1, wherein the vasoactive compound is a vasodilator.

3. The implant of claim 2, wherein the vasodilator is selected from the group consisting of (a) a muscarinic agent, an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, a vasoactive prostaglandins, an endothelin-derived relaxation factor, a vasoactive intestinal polypeptide agonist, a smooth muscle relaxant, a leukotriene inhibitor, and pharmacologically active salts, esters, prodrugs, and metabolites thereof, and combinations of any of the foregoing.

4. The implant of claim 2, wherein the carrier is selected from the group consisting of biodegradable polymers and non-biodegradable polymers

5. The implant of claim 4, wherein the biodegradable polymers are selected from the group consisting of polylactides (PLAs), polyglycolides (PGAs), poly(lactide co-glycolides (PLGAs), polycaprolactone, polyanhydride, poly methyl vinyl ether maleic anhydride, polycarbonates, polyarylates, polydioxanone, polyhydroxyalkanoates, and chitosan.

6. The implant of claim 4, wherein the non-biodegradable polymers are selected from the group consisting of ethylcellulose, ethylvinyl acetate, polystyrene, ethylene vinyl acetate copolymers, polydimethyl siloxane, polyvinyl chloride and talc.

7. The implant of claim 2 wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator over a period of up to about seven days.

8. The implant of claim 2 wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator over a period of up to about ten days.

9. The implant of claim 2 wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator over a period of up to about twenty days.

10. The implant of claim 2 wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator over a period of up to about forty days.

11. The implant of claim 2 wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator over a period of up to about sixty days.

12. The implant of claim 2 wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator over a period of up to about eighty days.

13. The implant of claim 2 wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator over a period of up to about one hundred days.

14. The implant of claim 2 wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator over a period of up to about three years.

15. The implant of claim 2, wherein the carrier is associated with the vasodilator by mixing together the carrier and the implant so as to obtain a homogenous distribution of the vasodilator in the carrier.

16. an intraocular implant for treating an ocular condition, the implant comprising:

(a) a vasodilator compound, and;

(b) a biodegradable polymer associated with the vasoactive compound, thereby forming an intraocular implant suitable for treating an ocular condition, wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator compound over a period of up to about forty days.

17. The implant of claim 16 wherein the implant is structured to be placed in the vitreous of the eye.

18. The implant of claim 17 formed as a rod, a wafer, or a particle.

19. The implant of claim 18 which is formed by an extrusion process.

29. The method of claim 19, wherein the implant is placed in the eye with a 25-30 gauge syringe.

20. A method of making a biodegradable intravitreal implant, the method comprising the step of extruding a mixture of a vasodilator compound, and a biodegradable polymer, thereby making forming an intravitreal implant suitable for treating an ocular condition, wherein after in vivo placement of the implant the implant releases a therapeutically effective amount of the vasodilator compound over a period of up to about forty days.

21. The method of claim 20, wherein the polymer comprises a polymer selected from the group consisting of polylactides, poly (lactide-co-glycolides), and combinations thereof.

22. A method of improving or maintaining vision of an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a therapeutic agent which is a vasodilator wherein the implant degrades at a rate effective to sustain release of an amount of the therapeutic agent from the implant effective to improve or maintain vision in the eye of the patient.

23. The method of claim 22, wherein the method is effective to treat a retinal ocular condition.

24. The method of claim 23, wherein the ocular condition includes retinal damage.

25. The method of claim 24, wherein the ocular condition is glaucoma.

26. The method of claim 23, wherein the ocular condition is proliferative vitreoretinopathy.

27. The method of claim 22, wherein the implant is placed in the posterior of the eye.

28. The method of claim 22, wherein the implant is placed in the eye with a trocar.

30. A method for treating glaucoma by intravitreal administration of a sustained release drug delivery system comprising a biodegradable polymer and a therapeutically effective amount of a vasoactive agent associated with the polymer.

31. A method for improving vision, the method comprising the step of intraocular placement of an intraocular implant comprising a vasoactive compound and a carrier associated with the vasoactive compound.

32. A method to preventing vision loss, the method comprising the step of intraocular placement of an intraocular implant comprising a vasoactive compound and a carrier associated with the vasoactive compound.